Treating Alzheimer's disease by inactivating bioactive amyloid β peptide

Current Alzheimer Research

Volumn 3, Issue 2, 2006, Pages 129-135

  Liu, Yuanbin ^a   Schubert, David ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Amyloidogenesis; Bioactive amyloid species; Drug screening; MTT

Indexed keywords

AMYLOID BETA PROTEIN; CHLORPROMAZINE; CONGO RED; IRON DEUTEROPORPHYRIN 2,4 DIETHYLENE GLYCOL; MEPACRINE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; CELL ASSAY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DRUG POTENCY; DRUG SCREENING; NONHUMAN; PATHOPHYSIOLOGY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN POLYMERIZATION; PROTEIN TARGETING; RAT; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CELLS, CULTURED; HUMANS; PEPTIDE FRAGMENTS;

EID: 33645813416     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506776383077     Document Type: Review

References (43)

1. Travis J. Saving the mind faces high hurdles. Science. 309: 731-4 (2005)
2. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-6 (2002).
3. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5: 677-85 (2004).
4. Sipe JD. Amyloidosis. Ann Rev Biochem 61: 947-75 (1992).
5. Glenner GG, Eanes ED, Bladen HA, Linke RP and Termine JD. A comparison of native amyloid with synthetic protein fibrils. J Histochem Cytochem 22: 1141-58 (1974).
6. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38: 1682-87 (1988).
7. Delaere P, Duyckaerts C, Masters C, Beyreuther K, Piette F and Hauw JJ. Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci Lett 116: 87-93 (1990).
8. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13: 179-89 (1992).
9. Delaere P, He Y, Fayet G, Duyckaerts C and Hauw JJ. Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol. Aging. 14: 191-94 (1993).
10. Berr C, Hauw JJ, Delaere P, Duyckaerts C and Amouyel P. Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease. Neurosci Lett 178: 221-24 (1994).
11. Harper J.D. and Lansbury P.T. Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385-407 (1997).
12. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939-45 (1997).
13. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med 4: 97-100 (1998).
14. Lorenzo A and Yankner BA. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91: 12243-47 (1994).
15. Liu Y and Piasecki D. A cell-based method for the detection of nanomolar concentrations of bioactive amyloid. Anal Biochem 289: 130-136 (2001).
16. Klein WL, Krafft GA and Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219-24 (2001).
17. Caughey B and Lansbury Jr. PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26: 267-98 (2003).
18. Meda L, Cassatella MA, Szendrel GI, Otvos Jr. L, Baron P, Villalba M, et al. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 374: 647-50 (1995).
19. Hu J, Akama KT, Krafft GA, Chromy BA and Van Eldik LJ. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 785: 195-206 (1998).
20. Behl C, Davis JB, Lesley R and Schubert D. Hydrogen peroxide mediate amyloid β protein toxicity. Cell 77: 817-27 (1994).
21. Shearman MS, Ragan CI and Iversen LL. Inhibition of PC-12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid- mediated cell death. Proc Natl Acad Sci. USA 91: 1470-4 (1994).
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. J Immunol Methods 65: 55-63 (1983).
23. Liu Y, Peterson D, Kimura H and Schubert D. The mechanism of cellular MTT reduction. J Neurochem 69: 581-93 (1997).
24. Liu Y and Schubert D. Cytotoxic amyloid peptides inhibit cellular MTT reduction by enhancing MTT formazan exocytosis. J Neurochem 69: 2285-93 (1997).
25. Liu Y and Schubert D. Steroid hormones block amyloid fibrilinduced MTT formazan exocytosis: relationship to neurotoxicity. J Neurochem 71: 2322-29 (1998).
26. Liu Y, Peterson D and Schubert D. Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci USA 95: 13266-71 (1998).
27. Liu Y. Understanding the biological activity of amyloid proteins in vitro: from inhibited cellular MTT reduction to altered cellular cholesterol homeostasis. Prog Neuro-Psychopharmacol & Psychiat 23: 377-95 (1999).
28. Liu Y, Dargusch R, Banh C, Miller CA and Schubert D. Detecting bioactive amyloid β peptide species in Alzheimer's disease. J Neurochem 91: 648-56 (2004).
29. nd and Chisholm JC. The 'amyloid hypothesis' of AD: decoy or real McCoy? Trends Neurosci 20: 558-9 (1997).
30. Price DL and Sisodis SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 21: 479-505 (1998).
31. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-91 (2001).
32. Versijpt JJ, Dumont F, Van Laere KJ, Decoo D, Santens P, Audenaert K, et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study Eur Neurol 50: 39-47 (2003).
33. Mueller SG, Weiner MW, Thal LJ, Peterson RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroiamging Initiative (ADNI). Alzheimer's & Dementia 1: 55-66 (2005).
34. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim Biophys Acta 1502: 76-84 (2000).
35. Caughey WS, Raymond LD, Horiuchi M and Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 95: 12117-22 (1998).
36. Doh-Ura K, Iwaki T and Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74: 4894-7 (2000).
37. Korth C, May BC, Cohen FE and Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98: 9836-41 (2001).
38. Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, Groth DF et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35: 349-58 (1983).
39. Caughey BW, Dong A, Bhat S, Ernst D, Hayes SF and Caughey WS. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30: 7672-80 (1991).
40. Caughey B and Race RE. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 59: 768-71 (1992).
41. Schubert D, Heinemann S, Carlisle W, Tarika H, Kimes B, Steinbach JH, Culp W and Brandt BL. Clonal cell lines from the rat central nervous system. Nature 249: 224-7 (1974).
42. Levison SW and McCarthy KD. Astroglia in culture. In Culturing Nerve Cells (Banker G. and Goslin K., Eds.), pp. 309-336, MIT Press, Cambridge, MA (1992).
43. Day BJ, Shawen S, Liochev SI and Crapro JD. A metalloporpgyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J Pharmacol Exp Ther 275: 1227-1232 (1995).